Sanofi launches Probi Digestis® in Korea

Probi has signed a distribution and supply agreement with Sanofi. Following this
the Consumer Healthcare divison of Sanofi Korea is making a major launch of
Probi´s gut health product, Probi Digestis®starting in April 2014. Probi has
already delivered products and received substantial orders for the coming
quarters.

Sanofi is a leading Healthcare company with more than 100.000 employees
worldwide and plays an important role in the global probiotic consumer market.
Sanofi’s Consumer Healthcare division in Korea offers diverse vitamins,
minerals, and health supplements under the well-established Cenovis brand.
Sanofi Korea is one of the major players in dietary supplements in the mass
retail channel in Korea.

“Probiotics is the next major growth category in Korea and the launch of Probi
Digestis®will be our focus for the Cenovis brand in 2014 and 2015. In Probi
Digestis® we found a high quality probiotic product with good clinical
documentation and we plan to extend the Probi range further, so it will play an
important role in the Cenovis probiotic strategy going forward” says DongWoo
Shin, head of Consumer Healthcare Sanofi Korea.

Probi Digestis® will be launched in all channels Sanofi Korea is currently
operating in, mass retail, department stores, drugstore/pharmacy, internet and
TV home shopping. The product will be sold with Probi Digestis® predominantly
displayed on front of the pack and Sanofi will make substantial consumer
marketing investment during the launch.

“Probi is looking forward to further strengthen our presence in the fast growing
Asian markets together with Sanofi Korea and the strong Cenovis brand” says
Peter Nählstedt, CEO of Probi. Peter Nählstedt adds, “Sanofi is a strong global
player and has potential of quickly becoming one of our largest customers.”

The South Korean market for probiotic supplements is estimated to have a value
of USD 54 million. The annual growth rate over the past five years has been on
avarage 15 percent however the growth rate is expected to be even higher in the
coming years. The increasing health awareness and disposable income are positive
factors driving the market growth in Korea.

Probi Digestis® is based on Lactobacillus plantarum 299v (DSM 9843), which
targets bloating, gas formation and pain, common symptoms that are sometimes
mild or temporary but often more severe and diagnosed as IBS – Irritable Bowel
Syndrome.

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile
+46 705 38 88 64, e-mail: niklas.bjarum@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops
effective and well-documented probiotics. Through its research, Probi has
created a strong product portfolio in the gastrointestinal health and immune
system areas. The products are available to consumers in more than 30 countries
worldwide.  The customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments. Probi had
sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm,
Small-cap. Probi has approximately 3,500 shareholders. Read more on
www.probi.se.

ABOUT SANOFI
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’needs.  Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE:SNY). In Korea, Sanofi has four legal entities in the
fields of pharmaceuticals and consumer healthcare (sanofi-aventis Korea),
vaccines (Sanofi Pasteur), rare disease (Genzyme Korea), and animal health
(Merial Korea).